Prox Biosciences

Prox Biosciences is an early-stage biotechnology company focused on the design and development of multifunctional, targeted injectable biologics. The company utilizes a combination of high-throughput computational tools, antibody engineering, and advanced immunology to create therapeutic candidates for complex diseases, including lung cancer and Crohn's disease. Its scientific approach emphasizes translational science and the creation of efficient, sustainable drug discovery processes. Early research efforts have also included the development of aptamer-based diagnostic solutions, such as screening tools for protein biomarker assays.

By leveraging cutting-edge methods in immunology and structural biology, Prox Biosciences aims to address significant unmet medical needs and advance superior antibody drugs toward clinical application. The company operates with a collaborative, flat-structured team in Cambridge, Massachusetts, integrating diverse expertise to bridge the gap between biological discovery and clinical treatment. Through its commitment to rigorous science and therapeutic innovation, Prox Biosciences seeks to provide impactful solutions for patients suffering from challenging conditions, prioritizing both speed and efficacy in its drug development pipeline.